Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How do you sequence luspatercept and imetelstat for treatment of anemia in MDS?
Related Questions
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How do you approach management for CCUS with severe cytopenias?
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How do you approach the second-line treatment for a patient with high-risk myeloma relapse early post-autoHCT after Dara-RVD induction?
Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?
In patients who relapse during a treatment-free period after achieving remission on prior 1st/2nd generation TKI, what factors should be taken into consideration when restarting treatment?
